Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.75 |
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | PGK1 | P00558 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918795 | 0.89 | PDGFRB (0.59) | PDGFRBPDGFRAEGFRMAPK1ALOX15 | |
| SCHEMBL3908370 | 0.86 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRPGK1MAPK1 | |
| SCHEMBL3908116 | 0.79 | PDGFRB (0.73) | PDGFRBPDGFRAEGFRMAPK1MAPT | |
| SCHEMBL22792292 | 0.76 | ALOX15 (0.44) | PDGFRBPDGFRAMAPK1ALOX15HTT | |
| SCHEMBL29338738 | 0.76 | PDGFRB (0.71) | PDGFRBPDGFRAEGFRPGK1MAPK1 | |
| SCHEMBL3910327 | 0.74 | PDGFRB (0.78) | PDGFRBPDGFRAEGFRMAPK1HTT | |
| SCHEMBL1530816 | 0.74 | PDGFRB (0.55) | PDGFRBPDGFRAEGFRGAAMAPT | |
| SCHEMBL780389 | 0.74 | MAP4K4 (0.50) | PDGFRBPDGFRAEGFRMAPK1HTT | |
| SCHEMBL18171881 | 0.74 | PDGFRB (0.61) | PDGFRBPDGFRAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL8118643 | 0.72 | PDGFRB (0.62) | PDGFRBPDGFRAEGFRPGK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1140516-C | Can inhibit platelet-derived growth factor and/or p56lckQuinoline and quinoxaline compounds of tyrosine kinases | ���µ�˹ҩ�﹫˾ | 2004-03-03 | — | — | CN | claimed |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | AVENTIS PHARMACEUTICALS INC. | 2003-07-31 | — | — | US | claimed |
| CN-1342151-A | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (US) | 2002-03-27 | — | — | CN | claimed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | claimed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | claimed |
| CN-1261354-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | CN | claimed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| CN-100390155-C | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | disclosed |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6846815-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-25 | — | — | US | disclosed |
| CN-1140516-C | Can inhibit platelet-derived growth factor and/or p56lckQuinoline and quinoxaline compounds of tyrosine kinases | ���µ�˹ҩ�﹫˾ | 2004-03-03 | — | — | CN | disclosed |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | AVENTIS PHARMACEUTICALS INC. | 2003-07-31 | — | — | US | disclosed |
| CN-1342151-A | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (US) | 2002-03-27 | — | — | CN | disclosed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| CN-1261354-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | CN | disclosed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, ABL1 | PDGFRB 39/4885PDGFRA 45/4885EGFR 1465/4885 |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | LCK, NFATC1, MAP2K2 | PDGFRB 106/4885PDGFRA 299/4885EGFR 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.